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Since the 2002 Dusseldorf meeting, one new agent,
Benlysta, has been approved by the US Food and
Drug Administration for systemic lupus erythematosus.
Experiences from the field in conducting trials of all
the agents tested during this period have provided
valuable practical insights. There has been incremental
progress in defining the minimal clinically important
difference (MCID) of key disease manifestations and
the view is largely that of the health care providers
and not that of the person suffering the disease. This
basic methodological work on the MCID should
improve the efficiency and the clinical relevance of
future trials and their design.sures vary in their cost of administration, the laboratory
determinations needed to complete the evaluation, weight-Background
Clinical trials could provide answers more quickly and
be more useful to clinicians by addressing, in their con-
cept and design, what differences between the compared
interventions would be worth finding, what differences
would be clinically meaningful to a patient, or what dif-
ferences would be important to the clinicians treating
them. In the majority of trials, these are rarely dealt with
explicitly; or if they are, only arbitrarily. “Measurement
sensitivity”, the ability of a measure to show a difference,
is contrasted with “responsiveness”, the ability to measure
or capture a clinically meaningful or important difference
[1]. Highlighted as an issue in trial design almost 20 years
ago, the minimal clinically important difference (MCID)
[1] is the minimal change of an outcome that patients feel
as an important difference; however, the methods of* Correspondence: mhliang@partners.org
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ated [2].
In systemic lupus erythematosus (SLE), the clinical trial-
ists’ ultimate challenge, there has been progress manifest-
ation by manifestation. This review and related articles in
this issue update the state of the art for methods to deter-
mine a clinically meaningful difference.History of efforts to define meaningful responses
in SLE clinical trials
There are a number of valid, reproducible measures of
disease activity for SLE. They are highly correlated with
one another and capture change in the clinical status of
individuals and groups of patients. However, these mea-
ing of manifestations, and their “floor” or the minimum
activity captured. The British Isles Lupus Assessment
Group (BILAG) index, unique among the contemporary
disease activity measures, formed a nominal scale by grad-
ing the change in the disease state reflecting the physician’s
intention to treat or change treatment. Outcome Measures
in Rheumatology Clinical Trials (OMERACT), notably,
have attempted to include patients in their consensus
meetings.
In 1999, with dozens of new targets emerging for devel-
oping new therapies in SLE and pari passu with the emer-
gence of two new philanthropies in SLE—Rheuminations
funded by the largesse of Katherine and the late Arnold
Snider, and the Alliance for Lupus Research (ALR) by
Robert Wood “Woody” Johnson IV—the Board of the
American College of Rheumatology (ACR) charged a
committee to develop recommendations for response
criteria. The ACR provided minimal support to start the
project. In doing so they felt that, as a good faith agent in-
sulated from specific drug development, standardizing
such measures might have the same salutatory impact as
response criteria had in drug evaluations for rheumatoiddistributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
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Institute, Rheuminations, Biogen, and the ALR was critical
to the work but it took the in-kind contributions of many
individuals to move the efforts forward to completion.
The overall goal of the committee was to define response
by overall activity as well as the dominant manifestation
for which a therapy was being instituted. The committee
assumed that clinicians had a gestalt of overall disease
activity based on the patient’s symptoms, appearance,
physical signs, and various laboratory measurements. In
developing a therapeutic plan, clinicians would in addition
find something to “follow” using symptoms, physical signs
when present, and organ-specific tests when one organ sys-
tem was dominant and of particular concern. The work
built on a number of published scales and indices of dem-
onstrated reliability and validity [3] for assessing the phe-
nomena of active SLE. Using a secure-website Internet
survey, experts in SLE worldwide rated data on patients
observed over two or three different time points from
North America and Europe and determined whether the
patient had stayed the same, or had a meaningful improve-
ment or worsening. Operationally, “meaningful” was de-
fined for the raters as a change which would drive them to
stop, taper, or initiate a major therapy. The plan was to de-
termine the overall response and the response for individ-
ual organs and to set the criteria for “steroid sparing”.
Over 2 days in 2002 in Düsseldorf, Germany, involving
nominal group techniques, formal votes, and breakout
work groups, the committee (see acknowledgements in
[4]) empirically determined clinically important disease
changes as worsening, unchanged, and improved, and
mapped their qualitative assessments to six SLE activity
rating scales which had been carried out for each patient’s
visit independently. They also nominated reviewers of the
work. In a subanalysis, an identical cassette of five patient
courses were embedded in the exercise, to determine the
variation in what experts called worsening or improved.
Systematic searches for published techniques for
measuring change were performed and summarized for
breakout groups to examine options for rating change in
fatigue, cutaneous, hematologic, renal, pulmonary, mus-
culoskeletal, and neurocognitive manifestations of lupus.
When judged feasible, consensus on what constituted an
important worsening or improvement was determined.
The important covariates that should be collected on sub-
jects to interpret changes in clinical state were defined.
Hematologic, pulmonary, and musculoskeletal response
criteria have not been published from the exercise. Their
perceived need has not sustained further work at this
point that we are aware of.
Fatigue
Depending on its definition and ascertainment, the preva-
lence of fatigue in patients with SLE varies among studies.It is, however, often the most common and limiting con-
stitutional symptom for patients. Inherently a symptom,
there is little to be gained clinically in trying to validate it
objectively and the clinician usually notes its presence and
attempts to find a specific treatable cause before attribut-
ing it to SLE.
Various instruments have been used to access fatigue
in SLE; these include a Fatigue Visual Analogue Scale
(VAS-fatigue) [5] of one form or another, the Fatigue Se-
verity Scale (FSS) [6], the Chalder Fatigue Scale (ChFS)
[7], the Robert B. Brigham Multipurpose Arthritis
Center-Fatigue Scale (MAC-FS) [8], the Piper Fatigue
Scale (PFS) [9], the Short Form of the Medical Outcome
Study questionnaire plus 1 item for fatigue (SF20 + 1)
[10], the Fatigue Self-Efficacy Scale (FSES) [11], the Short
Form-36 vitality subscale (SF-36-V) [12], the Multidimen-
sional Assessment of Fatigue (MAF) [13], the Multidimen-
sional Fatigue Inventory (MFI-20) [14], and the Fatigue
Assessment Instrument (FAI) [15]. While many instru-
ments have been used once in published studies, the FSS
was used most frequently followed by VAS-fatigue, ChFS,
MAC-FS, and MAF.
A systematic review of fatigue scales in SLE by the
ACR Ad Hoc Committee on SLE Response Criteria for
Fatigue identified 15 instruments used in 34 studies of
SLE from 1970 to 2006 [16]. They found that the FSS,
FAI, and MAC-FS had their reliability and responsiveness
validated in patients with SLE. The group recommended
the FSS because it was developed in patients with SLE,
was most frequently used in SLE studies, and had demon-
strated psychometric properties. Since no studies had
evaluated the MCID for any of the instruments, the com-
mittee suggested that improvement of ≤15 % in the FSS
could be considered clinically important, and recom-
mended that more investigations were needed. In 2012,
another group published a systematic review to find 49
studies between 1980 and 2010 [17]. The instruments
used and their frequency of use were consistent with the
previous systematic review.
We searched studies of fatigue in SLE patients from
2011 to 2014 and found 26 studies. The FSS was again
used most frequently. Of the new studies since 2010,
the Functional Assessment of Chronic Illness Therapy—
Fatigue (FACIT-F) [18], the Fatigue Assessment Scale
(FAS) [19], the Paced Auditory Serial Addition Task
(PASAT) for cognitive fatigue, and the Profile of Mood
State (POMS) Fatigue—Inertia were newly introduced and
tapped into new constructs of fatigue in SLE patients.
Most of these studies from 1970 to 2014 were cross-
sectional and had no data on whether other comorbid
illnesses associated with fatigue were excluded.
Since the Düsseldorf meeting, there have been two
studies that estimated the MCID in fatigue in patients with
SLE. A study by Goligher et al. [20] used conversations
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and mapped them to the preconversation results of those
individuals’ completed FSS, MAF, MFI, CFS, FACIT-F,
ChFS, and visual analogue scale (VAS). Eighty patients
compared their fatigue with each other which was mea-
sured on a seven-point Likert scale. Results showed
that the MFI [14] and FACIT-F [18] were most sensi-
tive in assessing clinical improvements, with their nor-
malized MCIDs of -12 and -5.3 for better and 16 and 17.5
for worse, respectively.
Colangelo et al. took a different approach. Two consecu-
tive annual measurements of fatigue by VAS (as judged by
the patients) in a patient were compared with the global
rating of overall health on a five-point Likert scale [21].
The MCID in fatigue for better was -13.9 and for worse
was 9.1 on a VAS of 0–100. This was somewhat compar-
able with results from the study by Goligher et al., except
for reversal of range for better or worse, where a global
rating scale showed MCID of -2.9 for better and 14.8
for worse.
Both of these studies used the patient’s assessment
compared with other patients or themselves at a different
time point to anchor the assessment for better or worse.
Using patients’ assessment for anchoring the determin-
ation for better or worse is preferable when one wants an
individual evaluation and seems preferable to a com-
parison with others. Few persons have an opportunity to
compare themselves systematically with others.
We feel it prudent to build on these studies and efforts
and to recommend that, for instruments, the FSS or
FACIT-F are possibly more sensitive and of better reliabil-
ity and validity based on studies in Parkinson’s disease
[17] and should therefore be used, and that the MCIDs
determined by Goligher et al.’s study should be used un-
less there are better data. From our perspective VAS mea-
sures are not standardized sufficiently in terms of the time
period covered, the anchors, and the choice or inclusion
of a midpoint or as reliable as multidimensional, psycho-
metrically evaluated scales, and we would usually not rec-
ommend their use. However, we realize that the VAS may
be chosen because of other considerations. When it is
used, the MCID determined by Colangelo et al. should be
used as a starting point.
Skin
Cutaneous manifestations are often one of the most dis-
turbing manifestations for patients. A validated tool, the
Cutaneous Lupus Erythematosus Disease Area and Sever-
ity Index (CLASI) has good content validity and reliability
[22]. This is assessed as activity and damage. Erythema,
scale/hypertropy, mucous membrane lesions, and alopecia
are scored for activity assessment and dyspigmentation,
and scarring/atropy/panniculitis for damage assessment.
Clinical responsiveness has been studied in two studies.Bonilla-Martinez et al. [23] investigated the correlation
between the activity scores of the CLASI and improve-
ment of global skin health, pain, and itch in 11 patients
with cutaneous lupus erythematosus (CLE). Patients
were assessed at baseline and after 8 weeks with the
CLASI and physician’s and patient’s global assessment.
Using a two-point change in physician’s global assess-
ment as the MCID, it was estimated that the change of
11.3 in the CLASI activity score was the MCID for glo-
bal skin manifestation in CLE. It was also assessed for
correlation with global change in patient’s itching and
pain, which showed that a change of 4.1 and 9.2 in the
CLASI activity score was the MCID.
The second study by Klein et al. [24] assessed respon-
siveness of the CLASI in 74 patients with CLE or SLE,
comparing it with the physician’s assessment of improved,
unchanged, or worse between visits. They recommended a
four-point change in the CLASI as the cutoff point for
classifying patients as improving or not improved.
These studies have shown that the CLASI is responsive
and correlates well with change in patient skin manifesta-
tions in both CLE and SLE. However, the results from
these two studies of the MCID appear to be very different
even though they were carried out by investigators who
overlapped between the studies and we recommend that
further studies should be done to establish the MCID.
From a conceptual point of view we also note that the
MCID in these two studies is taken from the perspective
of the expert and not from the patient’s point of view—a
major goal of true patient-oriented research.
Neurocognitive impairment
Neurocognitive impairment in patients with SLE is the
most common neuropsychiatric syndrome in SLE. A
systematic review by the Ad Hoc Committee on Lupus
Response Criteria identified 142 studies investigating
neurocognitive impairment in patients with SLE, and se-
lected 25 for review based on their design and quality
[25]. Outcome measures of neurocognitive impairment
were assessed for quality and psychometric properties
along with subscales of the Systemic Lupus Erythemato-
sus Disease Activity Index (SLEDAI), the SLEDAI-2 K,
the Safety of Estrogens in Lupus Erythematosus: National
Assessment (SELENA)-SLEDAI, the Systemic Lupus Ac-
tivity Measure (SLAM), the SLAM—Revised (SLAM-R),
the European Consensus Lupus Activity Measure
(ECLAM), and the Responder Index for Lupus Erythema-
tosus (RIFLE) to reach a consensus on which measure
should be recommended and what their definition of
meaningful change should be.
To improve comparability of studies and the practical
acquisition of neurocognitive data longitudinally, the
committee asked neuropsychologists to come up with a
comprehensive 1-hour battery (the time needed to carry
Note: This article is part of the series ‘Measuring meaningful
change in lupus clinical trials’, edited by Matthew Liang and
Chan-Bum Choi. Other articles in this series can be found at
http://arthritis-research.com/series/trials.
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the ACR neurocognitive battery for assessment of neuro-
cognitive impairment in adults with SLE [26]. In addition,
the Cognitive Symptoms Inventory (CSI) was suggested as
a way to characterize the impact of the neurocognitive
ability on a patient’s ability to function. In the absence of
data, the MCID was determined by a vote. For the ACR
neurocognitive battery, the MCID was defined as a change
of ≥1.0 standard deviation (SD) with an effect size of ≥1.0
in a key domain; and for the CSI it was ≥1.0 SD with an
effect size of ≥1.0.
We were unable to find further studies on the topic
and in their absence recommend that the ACR neuro-
cognitive battery be used but that a patient-based study
of the MCID for the CSI should be a research priority.
Overall disease activity
In 2004, an ACR committee led by Dr Liang was charged
with the task of developing response criteria for SLE and
to define their MCID [4]. Experts in SLE were recruited
worldwide for an exercise on a secure website. They were
presented with vignettes constructed from medical re-
cords of 310 patients to evaluate the six instruments of
SLE overall assessment (BILAG, SLEDAI, SLAM-R,
ECLAM, SELENA-SLEDAI, and RIFLE) and to determine
their MCID. The MCID was defined as a minimum
change in the instrument by which expert physicians
would judge the patients as having improved or wors-
ened with >70 % probability. The MCIDs for im-
proved and worsened for each instrument were -7
and +8, -6 and +8, -4 and +6, -4 and +4, -7 and +8,
and -4 and +3, respectively.
Since the committee published its findings, several
studies have investigated the MCID in SLE disease activ-
ity indices. Gladman et al. [27] investigated the MCID
for SLEDAI using independent physician’s global assess-
ment in 230 patients. They suggested that flare is de-
fined as an increase in SLEDAI >3 and improvement is
defined as a reduction in SLEDAI >3. Yee et al. [28] used
change in therapy as the external reference for change in
disease activity to determine the MCID of SLEDAI-2 K
using prospective longitudinal data from 347 patients.
Although the treatment change was significantly associ-
ated with change in the SLEDAI-2 K score, the change
in score itself was not sufficient to explain the change in
therapy when it alone was used in a model. Receiver op-
erating characteristic curve analysis of cutoff points for
change in SLEDAI-2 K as predictors of change in ther-
apy showed the cutoff point as an increase ≥3 for wors-
ening and reduction, and ≥1 for improvement. However,
the results showed that SLEDAI-2 K should be used as a
continuous score and take the baseline score into ac-
count when assessing the MCID. The BILAG index was
not assessed for MCID, but sensitivity in assessing SLEdisease activity defined by change in treatment was dem-
onstrated [29, 30].
Summary
Since 2002, one new agent has been approved by the US
Food and Drug Administration for SLE. Experiences
from the field conducting trials of all the agents tested
during this period have provided valuable practical in-
sights. These insights harnessed with basic methodo-
logical work on the MCID should improve the efficiency
and the clinical relevance of future trials.Abbreviations
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